DELIVERY ORDER
ActiveSPE2DP26F7931
Department of Defense › Defense Logistics Agency › DLA TROOP SUPPORT
$20.1M
obligated · signed 4 months ago
8512255434!ANTIDOTE TREATMENT - NERVE AG
Performance timeline
Start
Jul 22, 2026
End
Apr 23, 2027
with all options
Loading status
This contract is likely in the recompete window
Ends with all options: Apr 23, 2027
MERIDIAN MEDICAL TECHNOLOGIES, LLC
Contract SPE2DP26F7931
UEI
VBM4PLZ9VBC4
Parent Company
ALTARIS, LLC
Capabilities & Certifications
Headquarters Location
Congressional District: 01
Defense.gov daily contract announcements that mention this PIID
Meridian Medical Technologies LLC, St. Louis, Missouri, has been awarded a maximum $75,240,000 modification (P00003) exercising the first one-year option period of a one-year base contract (SPE2DP-26-D-0001) with two one-year option periods for antidote treatment nerve agent auto-injector. This is a firm-fixed-price, indefinite-delivery/indefinite-quantity contract. The ordering period end date is Nov. 15, 2027. Using customers are Army, Navy, Air Force, Marine Corps, and Coast Guard. Type of appropriation is fiscal 2027 through 2028 defense working capital funds. The contracting activity is Defense Logistics Agency Troop Support, Philadelphia, Pennsylvania.
Current Obligation
$20,058,500
Base + Exercised Options
$20,058,500
Total Ceiling Value
$20,058,500
Contract Type
FIRM FIXED PRICE
Multi-Year Contract
NO
NAICS
BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING
PSC
DRUGS AND BIOLOGICALS
Place of Performance
Congressional District: 01
Awarding Agency
Funding Agency
Contract Vehicle
SPE2DP26D0001
IDCDepartment of Defense
Award type: SINGLE AWARD
Solicitation procedures, competition exceptions, labor standards and account totals.